US Senators press for details on Gilead’s Sovaldi pricing

12 July 2014

Adding to previous criticism from the likes of the medical humanitarian organization Medecins Sans Frontieres (MSF) and the World Health Organization, US Senate Finance Committee Chairman Ron Wyden (Democrat, Oregon) and senior Finance Committee member Chuck Grassley (Republican, Iowa) on Friday requested detailed pricing information from US anti-virals specialist Gilead Sciences (Nasdaq: GILD) on its costly new hepatitis C virus (HCV) drug Sovaldi (sofosbuvir).

Senators Wyden and Grassley, who have long championed transparency in health care, have asked Gilead for information about Sovaldi, which has been hailed as breakthrough treatment for the 3.2 million Americans infected with HCV.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK